Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Genocea presents preclinical data on inhibigen biology » 09:04
06/22/20
06/22
09:04
06/22/20
09:04
GNCA

Genocea

$2.35 /

+0.115 (+5.16%)

Genocea Biosciences…

Genocea Biosciences presented preclinical data that offers new and important insights into the biology and behavior of inhibitory neoantigens at the American Association for Cancer Research Virtual Annual Meeting II from June 22-24. The findings build on previous research presented at SITC 2019 which demonstrated that the presence of an Inhibigen in an otherwise protective immunotherapy can completely reverse anti-tumor responses. In the preclinical study, pro-tumor Inhibigen effects were found to be correlated with an increasingly immune-suppressive tumor microenvironment, including reduced TILs and enhanced expression of T cell exhaustion markers. Vaccination of tumor-bearing mice with a formulation containing an inhibigen impaired both tumor antigen specific and nonspecific T cell function by blocking their ability to secrete cytokines and kill tumor cells - an effect that abolished T cell responses to beneficial anti-tumor antigens. In addition, the poster presentation revealed that immunization with Inhibigens led to a reduction in T cell receptor expression of tumor-specific T cells, which further hindered T cell function and activity needed to produce a robust immune response. The analysis also demonstrated that the Inhibigen-specific responses are not mediated by regulatory T cells - a subset of T cells known to suppress immune responses.

ShowHide Related Items >><<
GNCA Genocea
$2.35 /

+0.115 (+5.16%)

GNCA Genocea
$2.35 /

+0.115 (+5.16%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
GNCA Genocea
$2.35 /

+0.115 (+5.16%)

Hot Stocks
Genocea files IND application for GEN-011 » 07:35
06/15/20
06/15
07:35
06/15/20
07:35
GNCA

Genocea

$2.31 /

-0.05 (-2.12%)

Genocea Biosciences…

Genocea Biosciences announced the filing of an Investigational New Drug Application with the U.S. Food and Drug Administration to begin a Phase 1/2a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy. The GEN-011 trial will evaluate patient safety, T cell proliferation and persistence, and clinical activity, with preliminary data expected mid-2021. The company said, "Powered by ATLAS, GEN-011 offers several advantages over TIL therapies, the gold standard for solid tumor adoptive cell therapy. Unlike TILs, GEN-011 does not require extra surgery or collection of viable tumor samples and uses peripheral blood in a rapidly scalable manufacturing process. This may enable access to a broader population of patients with advanced cancers, and may result in a cost of therapy that is favorable compared to TIL-based approaches. GEN-011 may also offer lasting clinical efficacy by targeting up to 30 relevant neoantigens with CD4+ and CD8+ memory T cells and avoiding pro-tumor Inhibigens that may be detrimental to clinical response."

ShowHide Related Items >><<
GNCA Genocea
$2.31 /

-0.05 (-2.12%)

GNCA Genocea
$2.31 /

-0.05 (-2.12%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
GNCA Genocea
$2.31 /

-0.05 (-2.12%)

Over a month ago
Hot Stocks
Genocea presents updated long-term data from GEN-009 Phase 1/2a trial » 08:11
05/29/20
05/29
08:11
05/29/20
08:11
GNCA

Genocea

$3.01 /

+0.075 (+2.56%)

Genocea Biosciences…

Genocea Biosciences presents updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company's lead neoantigen vaccine candidate. Data will be shared by Roger Cohen, M.D., University of Pennsylvania Abramson Cancer Center, during a video poster presentation at the virtual 2020 American Society of Clinical Oncology Annual Meeting on May 29, 2020 from 8:00 - 11:00 am EDT. Title: GEN-009, a neoantigen vaccine containing ATLAS-selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides. The analysis evaluates eight patients from Part A of the trial who were vaccinated with GEN-009 as adjuvant therapy, focusing on the onset and duration of induced immunity and clinical outcomes. Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year. All patients received dosing as planned, with five doses given over a six-month period with immune responses occurring rapidly after only two vaccinations. No significant adverse side effects were reported with the administration of GEN-009, with only mild symptoms associated with the vaccine adjuvant. In addition, there are several notable patient outcomes: Prior to the GEN-009 trial, one patient diagnosed with melanoma had progressed after treatment with a PD-1 antibody, an experimental vaccine and a CTLA-4 inhibitor. After GEN-009, the patient continues in remission for more than 12 months. A patient diagnosed with squamous cell cancer of the head and neck had experienced successively shorter remissions but is now exceeding previous remissions and approaching nine months progression free with GEN-009. Both CD8+ and CD4+ responses were measured in both ex vivo and in vitro assays and were detected as early as day 29 extending as far as 12 months. The Part B trial continues with patients diagnosed with advanced disease who are receiving GEN-009 in combination with standard of care regimens, including immune checkpoint inhibitors. This cohort will explore the vaccine's ability to reduce tumor size beyond the standard of care therapy alone.

ShowHide Related Items >><<
GNCA Genocea
$3.01 /

+0.075 (+2.56%)

GNCA Genocea
$3.01 /

+0.075 (+2.56%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
GNCA Genocea
$3.01 /

+0.075 (+2.56%)

Hot Stocks
Genocea announces material transfer, license option agreement with Shionogi » 07:33
05/19/20
05/19
07:33
05/19/20
07:33
GNCA

Genocea

$2.50 /

-0.02 (-0.79%)

, SGIOY

Shionogi

$0.00 /

+ (+0.00%)

Genocea Biosciences…

Genocea Biosciences (GNCA) announced it has entered into a material transfer agreement and exclusive license option with Shionogi (SGIOY) to develop a novel HSV-2 vaccine using Genocea's proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi will pay $2M for the exclusive option to evaluate the HSV-2 antigens and to negotiate a license prior to expiration of the MTA. Upon exercise of Shionogi's option, terms of the license are expected to include an upfront payment, regulatory and sales milestones, as well as tiered royalties. Final terms of the license agreement will be based on results of the MTA evaluation and overall diligence. If licensed, Shionogi will assume responsibility for global development and commercialization of the HSV-2 vaccine product.

ShowHide Related Items >><<
GNCA Genocea
$2.50 /

-0.02 (-0.79%)

GNCA Genocea
$2.50 /

-0.02 (-0.79%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
SGIOY Shionogi
$0.00 /

+ (+0.00%)

03/31/20 Jefferies
Shionogi downgraded to Hold from Buy at Jefferies
03/23/20 Jefferies
Shionogi upgraded to Buy from Hold at Jefferies
09/24/19 Jefferies
Shionogi initiated with a Buy at Jefferies
GNCA Genocea
$2.50 /

-0.02 (-0.79%)

Conference/Events
Genocea to hold a virtual KOL symposium » 11:25
05/12/20
05/12
11:25
05/12/20
11:25
GNCA

Genocea

$2.46 /

+0.02 (+0.82%)

Virtual Key Opinion…

Virtual Key Opinion Leader Symposium to provide a brief review of the current T cell therapy and the development of GEN-011 on May 12 at 12 pm. Webcast Link

ShowHide Related Items >><<
GNCA Genocea
$2.46 /

+0.02 (+0.82%)

GNCA Genocea
$2.46 /

+0.02 (+0.82%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
GNCA Genocea
$2.46 /

+0.02 (+0.82%)

Conference/Events
Genocea to hold a virtual KOL symposium » 04:55
05/12/20
05/12
04:55
05/12/20
04:55
GNCA

Genocea

$2.44 /

+0.21 (+9.42%)

Virtual Key Opinion…

Virtual Key Opinion Leader Symposium to provide a brief review of the current T cell therapy and the development of GEN-011 on May 12 at 12 pm. Webcast Link

ShowHide Related Items >><<
GNCA Genocea
$2.44 /

+0.21 (+9.42%)

GNCA Genocea
$2.44 /

+0.21 (+9.42%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
GNCA Genocea
$2.44 /

+0.21 (+9.42%)

Conference/Events
Genocea to hold a virtual KOL symposium » 16:59
05/08/20
05/08
16:59
05/08/20
16:59
GNCA

Genocea

$2.23 /

-0.14 (-5.91%)

Virtual Key Opinion…

Virtual Key Opinion Leader Symposium to provide a brief review of the current T cell therapy and the development of GEN-011 on May 12 at 12 pm. Webcast Link

ShowHide Related Items >><<
GNCA Genocea
$2.23 /

-0.14 (-5.91%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
Hot Stocks
Genocea expects cash, cash equivalents to support operations into 1Q21 » 07:17
04/30/20
04/30
07:17
04/30/20
07:17
GNCA

Genocea

$2.26 /

+0.035 (+1.57%)

Genocea expects that its…

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021.

ShowHide Related Items >><<
GNCA Genocea
$2.26 /

+0.035 (+1.57%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
Earnings
Genocea reports Q1 EPS (46c), consensus (35c) » 07:17
04/30/20
04/30
07:17
04/30/20
07:17
GNCA

Genocea

$2.26 /

+0.035 (+1.57%)

Genocea remains on track…

Genocea remains on track with its two differentiated clinical stage programs - GEN-009 and GEN-011. The GEN-009 phase 1/2a clinical trial has reached sufficient enrollment for Part B of the study, which evaluates GEN-009 in combination with standard-of-care ICI therapy. The company anticipates preliminary clinical results in Q3 2020. Genocea also intends to file an Investigational New Drug Application for GEN-011 later this quarter with preliminary clinical results expected in 1H 2021. Genocea will host a GEN-011 virtual symposium on May 12th at 12 p.m. EDT with Eric Tran, PhD, who generated transformational data showing the potential of TIL therapy as a National Cancer Institute fellow. Dr. Tran will provide a brief overview of the current T cell therapy landscape - including the evolution of adoptive cell therapy and the need for new approaches to improve patient outcomes. Genocea will provide an in-depth profile of GEN-011 - a potential best-in-class adoptive T cell therapy -targeting an unprecedented breadth of relevant neoantigens, avoiding unwanted expansion of deleterious T cells and employing peripheral blood in a rapidly scalable manufacturing process to treat large cancer patient populations. "Over the last quarter, we have conducted our GEN-009 clinical program and prepared GEN-011 for IND filing as planned," said Chip Clark, President and Chief Executive Officer, Genocea. "We remain focused on the opportunity to create life-changing medicines for cancer patients during these uncertain and challenging times."

ShowHide Related Items >><<
GNCA Genocea
$2.26 /

+0.035 (+1.57%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright
Over a quarter ago
Hot Stocks
Genocea expects GEN-011 IND filing in 2Q20  07:47
02/13/20
02/13
07:47
02/13/20
07:47
GNCA

Genocea

$2.23 /

+0.06 (+2.76%)

 
ShowHide Related Items >><<
GNCA Genocea
$2.23 /

+0.06 (+2.76%)

11/15/19 SVB Leerink
Genocea initiated with an Outperform at SVB Leerink
07/25/19 H.C. Wainwright
Genocea price target lowered to $32 from $42 at H.C. Wainwright
07/08/19 Stifel
Genocea resumed with a Buy at Stifel
06/03/19 H.C. Wainwright
Genocea price target raised to $42 from $5.75 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.